FDA Guidelines on Tobacco Product Analysis and Testing Methods Validation

Jan.07
FDA Guidelines on Tobacco Product Analysis and Testing Methods Validation
FDA releases finalized guidelines on tobacco product analysis testing methods, providing manufacturers with support for regulatory submissions.

On January 6, the U.S. Food and Drug Administration (FDA) released the final version of the "Validation and Confirmation of Tobacco Product Analysis Methods" guidance, providing information and recommendations for tobacco manufacturers to support their submissions.


This guide provides detailed instructions for manufacturers on how to submit verified and validated data on analysis procedures and testing methods to the FDA for use in submissions including premarket tobacco product applications, substantial equivalence reports, and modified risk tobacco product applications.


Before being able to legally sell new tobacco products or modified risk tobacco products in the United States, companies must first submit an application to the FDA and receive approval. These applications typically require data and information to support the analytical methods used for testing tobacco products, and this guideline provides manufacturers and laboratories with scientifically sound information organization and presentation methods.


The principles described in this guide can also be applied to the writing of reports on harmful and potentially harmful constituents data required by tobacco product manufacturers and importers.


The draft version of this guide was released in 2021, allowing the public to provide feedback on the content. After considering this feedback, the FDA made adjustments to the final version of the guide, including updating the definition of "tobacco products" to include non-tobacco nicotine, adjusting the content to reflect the final PMTA and SE regulations, and updating and adding definitions for multiple terms. The final version of the guide also includes updated examples of alternative validation methods.


These suggestions are not legally binding and do not create legal obligations. In addition, the FDA acknowledges that there may be alternative validation procedures, such as statistical testing, that differ from the recommendations in this guide.


For applicants looking to introduce new tobacco products into the market, the FDA promises to continue providing information and resource support, including this recently released guide. The FDA has already issued regulations such as the PMTA final rule and regularly posts additional resources on its website and social media, such as application tips and webinars.


Compliance experts and consultants have provided the following analysis of the guidelines.


The U.S. FDA has issued this guide to provide tobacco manufacturers with guidance on conducting scientific validation and confirmation of analytical testing methods when submitting PMTA (premarket tobacco product application), SE (substantial equivalence application), and MRTPA (modified risk tobacco product application). This guide focuses on analytical testing of tobacco product ingredients, components, and additives, as well as issues related to chemical stability testing of finished tobacco products. It can also be used to guide testing and analysis of harmful and potentially harmful constituents (HPHC) in finished tobacco products, as well as other smoke or aerosol emissions. The guide aims to assist tobacco product manufacturers and analytical laboratories in collecting and presenting scientifically valid data and information to support analytical methods for submission to regulatory authorities for finished tobacco products. The recommendations in this guide will help the FDA better understand and evaluate the reliability of the data provided in regulatory submissions.


Click to read the final version of the guidelines for the validation and confirmation of analytical methods for tobacco products.


Readers are welcome to leave comments and get in touch with 2Firsts. Please contact: info@2firsts.com, or connect with 2Firsts CEO Alan Zhao on LinkedIn.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Altria Q3 2025 Earnings Report: Net Revenue of $6.072 Billion and Launch of on!PLUS in the U.S.
Altria Q3 2025 Earnings Report: Net Revenue of $6.072 Billion and Launch of on!PLUS in the U.S.
Altria reported Q3 2025 net revenue of $6.072 billion, a 3.0% year-on-year decline. Adjusted EPS increased 3.6% to $1.45. The company expanded its share repurchase program to $2 billion and launched the on!PLUS nicotine pouch in Florida, North Carolina, and Texas.
Oct.31 by 2FIRSTS.ai
Russia’s FSB Seizes Illegal Vape Warehouse Worth USD 6 Million
Russia’s FSB Seizes Illegal Vape Warehouse Worth USD 6 Million
Russia’s Federal Security Service (FSB) in the Tula Region dismantled an underground warehouse containing counterfeit vape products worth over 500 million rubles (approximately USD 6 million). A 27-year-old suspect was detained and faces up to 12 years in prison.
Nov.06 by 2FIRSTS.ai
AIRSCREAM Solidifies South African Leadership & Championing Truth in Vaping
AIRSCREAM Solidifies South African Leadership & Championing Truth in Vaping
As South Africa’s leading lifestyle vaping brand, AIRSCREAM is accelerating its regional growth strategy with the launch of its bold new initiative, “Trust ML, Not Puff.” The campaign calls for factual, millilitre (ml)-based transparency across the vaping industry, directly confronting misleading puff-count marketing practices and promoting clear, standardised information that reflects the true value and capacity of vaping products.
Nov.28
Lancet Study Finds Rising Use of Nicotine Pouches in Britain
Lancet Study Finds Rising Use of Nicotine Pouches in Britain
A study published in The Lancet has found that nicotine pouch use is increasing in Britain, particularly among young men. Usage among people aged 16 to 24 has risen sharply since early 2022.
Dec.17 by 2FIRSTS.ai
Alan Zhao: What Altria’s on! PLUS Authorization Really Signals About FDA PMTA Enforcement
Alan Zhao: What Altria’s on! PLUS Authorization Really Signals About FDA PMTA Enforcement
In this in-depth commentary for 2Firsts, Alan Zhao examines what Altria’s on! PLUS authorization really signals about FDA PMTA enforcement. Beyond the headline approval, FDA’s language, process design and product choices offer rare insight into how nicotine pouch regulation is taking shape—and what it means for industry compliance, in one of the earliest expert reads of the decision.
Regulations
Dec.20
From Partnership to Acquisition: Why KT&G Is Betting on the Global Nicotine Pouch Market
From Partnership to Acquisition: Why KT&G Is Betting on the Global Nicotine Pouch Market
As global competition in the nicotine pouch market accelerates, Korea’s tobacco major KT&G has moved with a “Partnership + Acquisition” strategy, teaming up with Altria to acquire Nordic pouch maker Another Snus Factory (brand “LOOP”). Why deploy capital now, and why take this route? Drawing on company disclosures, regulatory monitoring and on-site observations from InterTabac Dortmund, 2Firsts analyzes KT&G’s strategic calculus and the signals behind this move.
Nov.05